First Header Logo Second Header Logo

Connection

Herbert Bonkovsky to Liver Cirrhosis

Back to Details
This is a "connection" page, showing publications Herbert Bonkovsky has written about Liver Cirrhosis.
Herbert Bonkovsky
Connection Strength
3.452
Liver Cirrhosis
  1. Maddukuri VC, Russo MW, Ahrens WA, Emerson SU, Engle RE, Purcell RH, Thompson EB, Bonkovsky HL. Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient. Dig Dis Sci. 2013 Aug; 58(8):2413-6.
    View in: PubMed
    Score: 0.421
  2. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31.
    View in: PubMed
    Score: 0.272
  3. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis. 2005 Nov; 25(4):461-72.
    View in: PubMed
    Score: 0.252
  4. Salaye L, Bychkova I, Sink S, Kovalic AJ, Bharadwaj MS, Lorenzo F, Jain S, Harrison AV, Davis AT, Turnbull K, Meegalla NT, Lee SH, Cooksey R, Donati GL, Kavanagh K, Bonkovsky HL, McClain DA. A Low Iron Diet Protects from Steatohepatitis in a Mouse Model. Nutrients. 2019 Sep 10; 11(9).
    View in: PubMed
    Score: 0.165
  5. Li T, Eheim AL, Klein S, Uschner FE, Smith AC, Brandon-Warner E, Ghosh S, Bonkovsky HL, Trebicka J, Schrum LW. Novel role of nuclear receptor Rev-erba in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology. 2014 Jun; 59(6):2383-96.
    View in: PubMed
    Score: 0.114
  6. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology. 2012 Jul; 56(1):300-10.
    View in: PubMed
    Score: 0.100
  7. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr; 32(4):665-74.
    View in: PubMed
    Score: 0.096
  8. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
    View in: PubMed
    Score: 0.092
  9. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12.
    View in: PubMed
    Score: 0.090
  10. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9.
    View in: PubMed
    Score: 0.088
  11. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010 Oct; 8(10):877-83.
    View in: PubMed
    Score: 0.086
  12. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010 Feb; 51(2):585-94.
    View in: PubMed
    Score: 0.085
  13. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr; 31(7):719-34.
    View in: PubMed
    Score: 0.084
  14. Chawla RK, Wolf DC, Kutner MH, Bonkovsky HL. Choline may be an essential nutrient in malnourished patients with cirrhosis. Gastroenterology. 1989 Dec; 97(6):1514-20.
    View in: PubMed
    Score: 0.084
  15. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec; 50(6):1738-49.
    View in: PubMed
    Score: 0.084
  16. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37.
    View in: PubMed
    Score: 0.081
  17. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58.
    View in: PubMed
    Score: 0.081
  18. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug; 137(2):549-57.
    View in: PubMed
    Score: 0.081
  19. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
    View in: PubMed
    Score: 0.078
  20. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48.
    View in: PubMed
    Score: 0.077
  21. Bonkovsky HL, Hartle DK, Mellen BG, Kutner M, Galambos JT. Plasma concentrations of immunoreactive atrial natriuretic peptide in hospitalized cirrhotic and noncirrhotic patients: evidence for a role of deficient atrial natriuretic peptide in pathogenesis of cirrhotic ascites. Am J Gastroenterol. 1988 May; 83(5):531-5.
    View in: PubMed
    Score: 0.075
  22. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008 Mar; 47(3):789-98.
    View in: PubMed
    Score: 0.074
  23. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12.
    View in: PubMed
    Score: 0.074
  24. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):245-54.
    View in: PubMed
    Score: 0.069
  25. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology. 2006 Nov; 131(5):1440-51.
    View in: PubMed
    Score: 0.067
  26. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7.
    View in: PubMed
    Score: 0.066
  27. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92.
    View in: PubMed
    Score: 0.062
  28. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, Mehta S, Koff RS, Liu Q, Hsieh CC. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol. 2002 Dec; 37(6):848-54.
    View in: PubMed
    Score: 0.052
  29. Bonkovsky HL, Obando JV. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. Curr Gastroenterol Rep. 1999 Feb-Mar; 1(1):30-7.
    View in: PubMed
    Score: 0.040
  30. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997 Mar; 25(3):759-68.
    View in: PubMed
    Score: 0.035
  31. Banner BF, Allan C, Smith L, Savas L, Bonkovsky HL. Effect of interferon therapy on bile duct inflammation in hepatitis C. Virchows Arch. 1996 Jul; 428(4-5):253-9.
    View in: PubMed
    Score: 0.033
  32. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis. 1996 Feb; 16(1):65-82.
    View in: PubMed
    Score: 0.032
  33. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 1995 Apr; 103(4):419-24.
    View in: PubMed
    Score: 0.030
  34. Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB. Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011 Oct; 9(10):902-909.e1.
    View in: PubMed
    Score: 0.023
  35. Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: fad or future of liver disease. World J Gastroenterol. 2011 May 28; 17(20):2536-42.
    View in: PubMed
    Score: 0.023
  36. Bonkovsky HL. Iron and the liver. Am J Med Sci. 1991 Jan; 301(1):32-43.
    View in: PubMed
    Score: 0.023
  37. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol. 2011 May; 106(5):884-93.
    View in: PubMed
    Score: 0.022
  38. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan; 138(1):136-46.
    View in: PubMed
    Score: 0.021
  39. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec; 137(6):1986-94.
    View in: PubMed
    Score: 0.021
  40. Bonkovsky HL, Bonkovsky ML, Anderson PB, Rothstein RI, Erkkinen JF. Atenolol for prevention of rebleeding from esophageal varices in hepatic cirrhosis: results of a controlled, randomized pilot study. Am J Gastroenterol. 1989 Jun; 84(6):681-3.
    View in: PubMed
    Score: 0.020
  41. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41.
    View in: PubMed
    Score: 0.020
  42. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec; 44(6):1675-84.
    View in: PubMed
    Score: 0.017
  43. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12.
    View in: PubMed
    Score: 0.017
  44. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005 Sep; 43(3):434-41.
    View in: PubMed
    Score: 0.016
  45. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.